INOVIO to present new DNA medicine advances for hemophilia at global conference

INOVIO, a biotech company specializing in DNA medicines, announced it will present its latest research on DNA-encoded protein therapies for hemophilia at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026. The presentations will showcase INOVIO's technology producing functional Factor VIII protein in mouse models, demonstrating potential treatment for Hemophilia A. This highlights INOVIO's progress in developing innovative DNA medicines that could improve treatment options for bleeding disorders. Abstracts from the presentations will be available on INOVIO's website after the event.